Evaluation of recombinant sporozoite antigen SPAG-1 as a vaccine candidate against Theileria annulata by the use of different delivery systems

dc.creatorBoulter, N.
dc.creatorBrown, D.
dc.creatorWilkie, G.
dc.creatorWilliamson, S.
dc.creatorKirvar, E.
dc.creatorKnight, P.
dc.creatorGlass, E.
dc.creatorCampbell, J.
dc.creatorMorzaria, S.P.
dc.creatorNene, Vishvanath M.
dc.creatorMusoke, A.J.
dc.creatorOliveria, C. de
dc.creatorGubbels, M.J.
dc.creatorJongejan, F.
dc.creatorHall, R.
dc.date1999-09
dc.date2013-06-11T09:24:55Z
dc.date2013-06-11T09:24:55Z
dc.date.accessioned2026-06-27T16:47:23Z
dc.descriptionThe major sporozoite surface antigen of Theileria annulata (SPAG-1) is a candidate for inclusion in a subunit vaccine. In this paper we summarize the results of 4 vaccination experiments using recombinant SPAG-1 expressed in different systems and presented in different adjuvants. The antigen has been presented as either a C terminal 108 amino acid peptide (called SR1) expressed as both beta-galactosidase and hepatitis B core antigen fusions or as a full-length form expressed as a GST fusion with an N terminal His6 tag. Different adjuvants, namely Freund's, saponin, ISCOMs and a proprietary adjuvant supplied by SmithKline Beecham were used, which are called SKBA. The data point to the conclusion that SPAG-1 can elicit partial protection and is therefore suitable for inclusion in an eventual multicomponent subunit vaccine.
dc.identifierhttps://hdl.handle.net/10568/29793
dc.identifier.urihttp://hdl.handle.net/123456789/133198
dc.languageen
dc.publisherWiley
dc.rightsLimited Access
dc.sourceTropical Medicine & International Health;4(9): A71-A77
dc.subjecttheileria parva
dc.subjectvaccines
dc.subjectantigens
dc.subjectsporozoites
dc.subjectimmunization
dc.subjectcalves
dc.titleEvaluation of recombinant sporozoite antigen SPAG-1 as a vaccine candidate against Theileria annulata by the use of different delivery systems
dc.typeJournal Article

Archivos